Skip to main content

Mintz Guides Inhibrx from Inception through Nearly $137 Million IPO, and Beyond

Firm Demonstrates Life Sciences, Venture Capital, and General Corporate Expertise in West Coast Offices

Mintz advised Inhibrx, Inc. (Inhibrx; Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, in its $136.9 million initial public offering (IPO), which consisted of 8,050,000 shares of common stock at a price to the public of $17 per share, and closed on August 21.

Headquartered in La Jolla, CA, Inhibrx is a clinical-stage biotechnology company utilizing diverse methods of protein engineering to develop a broad pipeline of biologic therapeutic candidates for oncology and orphan diseases.

Significantly, Mintz has represented Inhibrx since its inception and helped the company implement a unique structure to develop and finance its business, including through two licensing deals, as well as two private financings involving unique corporate and tax structuring and international aspects.

“It has been exciting to support Inhibrx’s strategic business goals over the past ten years,” said Mintz Member and Co-chair of the firm’s Venture Capital & Emerging Companies Practice Jeremy Glaser. “It is also deeply rewarding to see a longstanding client succeed in the competitive biotech startup landscape and amid challenging economic circumstances.”

Since 2006, Mintz’s West Coast offices have continued to grow and strengthen proficiency across practice areas. The firm now boasts three offices in California — Los Angeles, San Diego, and San Francisco — with more than 100 attorneys with expertise in life sciences, technology, venture capital and emerging companies, securities and capital markets, mergers and acquisitions, intellectual property, employment law, product liability, class actions, real estate, and more. Over the past year, Mintz has added a number of leading attorneys to its Corporate & Securities Practice on the West Coast, including the additions of Members Andrew Thorpe, Melissa Frayer, and Stephen Osborn, all based in San Francisco.

Bolstered by the expertise of many West Coast practitioners, Mintz is one of the leading law firms for the life sciences industry. More than two dozen California-based attorneys hold PhDs in biology, chemistry, genetics, immunology, neuroscience, pharmacology, electrical engineering, and environmental engineering, and several others hold technical masters degrees spanning the life sciences. The firm’s attorneys advise hundreds of businesses and other organizations across the life sciences ecosystem — from start-ups and emerging growth companies to large public companies as well as venture capital firms, investment banks, and research and academic institutions — on pivotal deals, mission-critical disputes, intellectual property, and regulatory matters.

The Mintz team that advised Inhibrx in its IPO was led by Mr. Glaser and Melanie Ruthrauff Levy, and included Member and Co-chair of the Securities & Capital Markets Practice Megan Gates, Members Marc Morley, Joanne Hawana, and a San Diego-based team of Associates including Jenna Stewart, Joshua Summers, Jason Miller, and Melissa Brayman.